AMENDMENT OF SOLICITATION
-------------------------

1.   AMENDMENT OF SOLICITATION No.:  RFP-NIH-NIAID-DAIDS-96-14

2.   AMENDMENT NO.:  1

3.   DATED:  June 22, 1995

4.   EFFECTIVE DATE:  See Item 9C.    

5.   ISSUED BY:  National Institutes of Health
                 Contract Management Branch, NIAID
                 Solar Building, Room 3C07
                 6003 Executive Boulevard, MSC 7610
                 Bethesda, Maryland 20892-7610

6.   NAME AND ADDRESS OF CONTRACTOR:  To all Offerors 

7.   THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS:  
    
     The above numbered solicitation is amended as set forth in
     Item 8.  The hour and date specified for receipt of Offers
     is NOT extended.  Offerors must acknowledge receipt of this
     amendment prior to the hour and date specified in the
     solicitation by acknowledging receipt of this amendment on
     each copy of the offer submitted.  FAILURE OF YOUR
     ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE
     RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY
     RESULT IN REJECTION OF YOUR OFFER.  If by virtue of this
     amendment you desire to change an offer already submitted,
     such change may be made by telegram or letter, provided each
     telegram or letter makes reference to the solicitation and
     this amendment, and is received prior to the opening hour and
     date specified.

8.   DESCRIPTION OF AMENDMENT (Organized by UCF section headings,
     including solicitation/contract subject matter where
     feasible.)

         RFP TITLE: "Central Immunology Laboratory for AIDS Vaccine 
                     Clinical Trials"

         PURPOSE:  To amend the following items of the Central      
                   Immunology Laboratory for AIDS Vaccine Clinical  
                   Trials Work Statement (Attachment A of RFP       
                   NIH-NIAID-DAIDS-96-14):

            1.   Note 3 to Offeror is hereby revised as follows:

                 Note 3 to Offeror:  Detailed assay procedures for  
                 the ELISAs, including sample protocols, should be  
                 included in the Technical Proposal.  At the        
                 present time the Government does not know how many 
                 HIV-specific ELISAs will be required.  For         
                 purposes of preparing a budget, the Offeror should 
                 assume that sera from approximately 1200           
                 volunteers at 12 timepoints/volunteer will be      
                 assayed annually.  OFFERORS ARE TO BUDGET FOR 3    
                 ANTIGENS PER TIMEPOINT.  The offeror may assume    
                 that the Vaccine Developer or NIAID will provide   
                 all the HIV-1 proteins, but usually only some of   
                 the peptides for these analyses.  Therefore, the   
                 Offeror should include in the Budget costs to      
                 synthesize or purchase peptides, such as those     
                 corresponding to the V3 sequence of HIV-1 envelope 
                 gp120.


            2.   The last sentence of Note 22 to Offeror is hereby  
                 revised as follows:

                 For purposes of preparing a budget, the Offeror    
                 should assume that 100 of assays (1) - (5) above   
                 will be required each year and GENETIC SEQUENCES   
                 CORRESPONDING TO 50 HIV-1 ISOLATES will be         
                 required per year.

               
            3.   Note 27 to Offeror is hereby revised as follows:

                 Note 27 to Offeror:  At the present time the       
                 Government does not know what quantity of          
                 specimens will be shipped to the Offeror's         
                 laboratory or from the Offeror's laboratory.  For  
                 purposes of preparing a budget, the Offeror should 
                 assume that shipping costs for approximately 500   
                 INDIVIDUAL SHIPMENTS will be borne by the Offeror. 
                 For budgeting purposes, assume that all other      
                 specimen shipping costs will be borne by other     
                 NIAID contractors.                 


     Except as provided herein, all terms and conditions of the
     document referenced in Item 1, as heretofore changed,
     remains unchanged and in full force and effect.

*******************************************************************
9A.   NAME AND TITLE OF CONTRACTING OFFICER (type or print):
      Toni A. Kuhn, Chief, AIDS Preclinical Research Contract       
       Section, Contract Management Branch, NIAID
 
9B.   UNITED STATES OF AMERICA
      BY (Signature of Contracting Officer) _______/s/___________

9C.   DATE SIGNED:  June 22, 1995